Targeting the IL-15/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo.

Front Immunol

Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Vitiligo is a chronic autoimmune disorder in which melanocyte-specific CD8 T cells destroy pigment-forming cells, producing persistent depigmented macules. Recurrence after treatment implicates tissue-resident memory T (TRM) cells that are maintained by interleukin-15 (IL-15) signaling. Here we review current insights into TRM-cell biology, summarize experimental and emerging clinical data targeting the IL-15/CD122 axis-including the ongoing Phase 2a AMG 714 trial-and discuss combination strategies with approved topical Janus kinase inhibitors such as ruxolitinib cream. Disrupting IL-15 may offer durable repigmentation with minimal systemic immunosuppression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336204PMC
http://dx.doi.org/10.3389/fimmu.2025.1639732DOI Listing

Publication Analysis

Top Keywords

targeting il-15/cd122
8
il-15/cd122 signaling
4
signaling pathway
4
pathway reversing
4
reversing trm
4
trm cell-mediated
4
cell-mediated immune
4
immune memory
4
memory vitiligo
4
vitiligo vitiligo
4

Similar Publications

Targeting the IL-15/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo.

Front Immunol

August 2025

Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Vitiligo is a chronic autoimmune disorder in which melanocyte-specific CD8 T cells destroy pigment-forming cells, producing persistent depigmented macules. Recurrence after treatment implicates tissue-resident memory T (TRM) cells that are maintained by interleukin-15 (IL-15) signaling. Here we review current insights into TRM-cell biology, summarize experimental and emerging clinical data targeting the IL-15/CD122 axis-including the ongoing Phase 2a AMG 714 trial-and discuss combination strategies with approved topical Janus kinase inhibitors such as ruxolitinib cream.

View Article and Find Full Text PDF